A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND COHORT EXPANSION STUDY OF THE SAFETY AND EFFICACY OF ANTI-CD70 ALLOGENIC CRISPR-CAS9-ENGINEERED T CELLS (CTX130) IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY T OR B CELL MALIGNANCIES
- Registry ID
- CRSP-ONC-004
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- CRISPR THERAPEUTICS INC
- Start date
- 2023-08-07
- Last update
- 2020-05-19
Conditions
- T CELL MALIGNANCY
- B CELL MALIGNANCY
View on source registry